AIDX
20/20 Biolabs, Inc. Common Stock
NASDAQ · Healthcare · Medical - Devices · US
$0.59
−3.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.0M | 2.0M | 1.8M | 1.4M | 11.1M |
| Cost of Revenue | 1.4M | 1.4M | 1.4M | 1.3M | 5.9M |
| Gross Profit | 643.1K | 604.5K | 360.3K | 109.1K | 5.1M |
| Operating Expenses | |||||
| R&D Expense | 672.7K | 592.6K | 1.3M | 1.4M | 120.0K |
| SG&A Expense | 4.4M | 3.3M | 4.8M | 5.1M | 3.3M |
| General & Admin Expense | 1.4M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 5.0M | 3.9M | 6.0M | 6.5M | 3.4M |
| Cost and Expenses | 6.4M | 5.4M | 7.4M | 7.8M | 9.4M |
| Operating Income (EBIT) | (4.4M) | (3.3M) | (5.7M) | (6.4M) | 1.7M |
| Non-Operating | |||||
| Interest Income | 28.4K | 21.4K | 79.5K | 209.2K | 68.4K |
| Interest Expense | 693.8K | 156.2K | 12.6K | 27.9K | 15.7K |
| Net Interest Income | (665.4K) | (134.8K) | 66.8K | 181.2K | 52.7K |
| Other Non-Op Income/Expense | (1.4M) | (407.9K) | 109.4K | (29.8K) | 508.0K |
| Non-Operating Income (excl Interest) | 464.5K | 251.7K | — | — | — |
| EBT (Pre-Tax Income) | (5.8M) | (3.7M) | (5.6M) | (6.4M) | 2.2M |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (5.8M) | (3.7M) | (5.6M) | (6.4M) | 2.2M |
| Earnings from Cont. Ops | (5.8M) | (3.7M) | (5.6M) | (6.4M) | 2.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.0M) | (3.7M) | (5.6M) | (6.4M) | 2.2M |
| Per Share | |||||
| Basic EPS | ($0.76) | ($0.60) | ($1.16) | ($1.34) | $0.46 |
| Diluted EPS | ($0.76) | ($0.60) | ($1.16) | ($1.34) | $0.23 |
| Revenue Per Share | $0.19 | $0.33 | $0.37 | $0.30 | $2.32 |
| Shares | |||||
| Basic Shares Outstanding | 10.8M | 6.3M | 4.8M | 4.8M | 4.8M |
| Diluted Shares Outstanding | 10.8M | 6.3M | 4.8M | 4.8M | 9.5M |
| Profitability Metrics | |||||
| EBITDA | (4.8M) | (3.5M) | (5.5M) | (6.2M) | 2.0M |
| D&A | 68.6K | 78.0K | 135.8K | 167.3K | 288.7K |
| EBIT | (4.9M) | (3.6M) | (5.7M) | (6.4M) | 1.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026